Yamamoto Ryuichi, Takahashi Masatomo, Osafune Yasuyo, Chinen Katsuya, Kato Shingo, Nagoshi Sumiko, Yakabi Koji
Ryuichi Yamamoto, Masatomo Takahashi, Yasuyo Osafune, Katsuya Chinen, Shingo Kato, Sumiko Nagoshi, Koji Yakabi, Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Saitama 350-8550, Japan.
World J Gastrointest Endosc. 2015 Jul 25;7(9):889-94. doi: 10.4253/wjge.v7.i9.889.
To evaluate the efficacy and safety of single-step endoscopic placement of self-expandable metallic stents (SEMS) for treatment of obstructive jaundice.
A retrospective study was performed among 90 patients who underwent transpapillary biliary metallic stent placement for malignant biliary obstruction (MBO) between April 2005 and October 2012. The diagnosis of primary disease and MBO was based on abdominal ultrasound, computed tomography, magnetic resonance imaging, endoscopic ultrasound, endoscopic retrograde cholangiopancreatography with brush cytology, biopsy, and/or a combination of these modalities. The type of SEMS (covered or non-covered, 8 mm or 10 mm in diameter) was determined by the endoscopist. Ninety patients were divided into two groups: group 1 (49 patients) who underwent a single-step SEMS placement and group 2 (41 patients) who underwent a two-step SEMS placement. The technical success rate, complication rate, stent patency, and patient survival rate were compared between the groups. In addition, to identify the clinical prognostic factors associated with patient survival, the following variables were evaluated in Cox-regression analysis: gender, age, etiology of MBO (pancreatic cancer or non-pancreatic cancer), clinical stage (IVb; with distant metastases or IVa >; without distant metastases), chemotherapy (with or without), patency of the stent, and the use of single-step or two-step SEMS.
Immediate technical success was achieved in 93.9% (46/49) in group 1 and in 95.1% (39/41) in group 2, with no significant difference (P = 1.0). Similarly, there was no difference in the complication rates between the groups (group 1, 4.1% and group 2, 4.9%; P = 0.62). Stent failure was observed in 10 cases in group 1 (20.4%) and in 16 cases in group 2 (39.0%). The patency of stent and patient survival revealed no difference between the two groups with Kaplan-Meier analysis, with a mean patency of 111 ± 17 d in group 1 and 137 ± 19 d in group 2 (P = 0.91), and a mean survival of 178 ± 35 d in group 1 and 222 ± 23 d in group 2 (P = 0.57). On the contrary, the number of days of hospitalization associated with first-time SEMS placement in group 1 was shorter when compared with that number in group 2 (28 vs 39 d; P < 0.05). Multivariate analysis revealed that a clinical stage of IVa > (P = 0.0055), chemotherapy (P = 0.0048), and no patency of the stent (P = 0.011) were independent prognostic factors associated with patient survival.
Our results showed that single-step endoscopic metal stent placement was safe and effective for treating obstructive jaundice secondary to various inoperable malignancies.
评估单步内镜置入自膨式金属支架(SEMS)治疗梗阻性黄疸的疗效和安全性。
对2005年4月至2012年10月期间90例行经乳头胆管金属支架置入术治疗恶性胆管梗阻(MBO)的患者进行回顾性研究。原发疾病和MBO的诊断基于腹部超声、计算机断层扫描、磁共振成像、内镜超声、经内镜逆行胰胆管造影术联合刷检细胞学检查、活检及/或这些检查方法的联合应用。SEMS的类型(覆膜或非覆膜,直径8mm或10mm)由内镜医师确定。90例患者分为两组:第1组(49例)行单步SEMS置入术,第2组(41例)行两步SEMS置入术。比较两组的技术成功率、并发症发生率、支架通畅率和患者生存率。此外,为确定与患者生存相关的临床预后因素,在Cox回归分析中评估以下变量:性别、年龄、MBO的病因(胰腺癌或非胰腺癌)、临床分期(IVb期;有远处转移或IVa期>;无远处转移)、化疗(有或无)、支架通畅情况以及单步或两步SEMS的使用。
第1组93.9%(46/49)、第2组95.1%(39/41)即刻获得技术成功,差异无统计学意义(P = 1.0)。同样,两组并发症发生率无差异(第1组4.1%,第2组4.9%;P = 0.62)。第1组10例(20.4%)、第2组16例(39.0%)观察到支架功能障碍。Kaplan-Meier分析显示两组支架通畅率和患者生存率无差异,第1组平均通畅时间为111±17天,第2组为137±19天(P = 0.91),第1组平均生存时间为178±35天,第2组为222±23天(P = 0.57)。相反,与第2组相比,第1组首次SEMS置入相关的住院天数更短(28天对39天;P<0.05)。多因素分析显示,IVa期>(P = 0.0055)、化疗(P = 0.0048)和支架不通畅(P = 0.011)是与患者生存相关的独立预后因素。
我们的结果表明,单步内镜金属支架置入术治疗各种无法手术切除恶性肿瘤继发的梗阻性黄疸安全有效。